Atlas First In Market With 30-Minute POC Molecular Test For Chlamydia
This article was originally published in Clinica
Executive Summary
Atlas Genetics is bringing to market the first point-of-care molecular diagnostic test for chlamydia that can deliver results in 30 minutes. The rapid turnaround time will hopefully reduce the number of patients who do not go back to retrieve their results and consequently not get the necessary treatment should they have the sexually transmitted infection (STI).
You may also be interested in...
Atlas Genetics Fundraising Pulls In New Chinese Investment
Atlas Genetics, a UK point-of-care molecular diagnostics developer, has raised $35m in Series D financing from an investor syndicate. The funding round attracted existing shareholders and new investment from Chinese in vitro diagnostic company Wondfo Biotech.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.